glp 1 addiction study IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1s Like Ozempic May Be
Description
Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies
The WHOs announcement came hours after Australia released a safety alert over the potential risk of suicidal thoughts and behaviours for people using the medicines.
Understanding GLP-1 drugs personal injury lawsuits in 2026
Clinical evidence shows GLP-1 medications can be effective at lower body weight goals when combined with personalized dosing and lifestyle support
Youre Eating Less
